Jim Simons’s Dermata Therapeutics DRMA Stock Holding History

Jim Simons’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-176	Closed	-$34K	–	3998
2023 Q1	$34K	Buy	+176	New	+$103K	﹤0.01%	3740
2022 Q1	–	Sell	-16	Closed	-$68K	–	4139
2021 Q4	$68K	Buy	+16	New	+$141K	﹤0.01%	3749

Other funds holding DRMA

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HWA

HCR Wealth Advisors Los Angeles, California $1.12B AUM 33.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jim Simons's DRMA Position: Q2 2023 in Review

Jim Simons sold out of Dermata Therapeutics (DRMA) in Q2 2023, closing a stake of 176 shares — an estimated $34K sold.

Jim Simons first reported a position in DRMA in Q4 2021 and held it in 2 quarters. The position peaked at $68K in Q4 2021. 8 funds tracked by Wall St. Rank hold DRMA as of Q2 2023.

Jim Simons reported no remaining Dermata Therapeutics position as of Q2 2023 after selling out during the quarter.
Jim Simons sold 176 Dermata Therapeutics shares in Q2 2023, an estimated $34K.
Jim Simons first reported a position in Dermata Therapeutics in Q4 2021 and held it in 2 quarters.
Jim Simons's Dermata Therapeutics position peaked at $68K in Q4 2021.
8 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.